{"id":"W2770975168","doi":"10.1001/jamaoncol.2017.5029","title":"Vemurafenib for <i>BRAF</i> V600–Mutant Erdheim-Chester Disease and Langerhans Cell Histiocytosis","year":2017,"lang":"en","type":"article","venue":"JAMA Oncology","topic":"Histiocytic Disorders and Treatments","field":"Medicine","cited_by":405,"is_retracted":false,"has_abstract":true,"ca_institutions":"Roche (Canada)","funders":"National Cancer Institute","keywords":"Vemurafenib; Medicine; V600E; Langerhans cell histiocytosis; Internal medicine; Progression-free survival; Melanoma; Oncology; Adverse effect; Positron emission tomography; Dermatology; Cancer research; Radiology; Chemotherapy; Disease; Mutation; Metastatic melanoma","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"not_applicable","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low","status":"direct model label, unvalidated"},{"model":"gpt","categories":[],"domain":null,"study_design":"design_other","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low","status":"direct model label, unvalidated"}],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001024276,0.0001653706,0.0003651594,0.00004924671,0.0003126628,0.00005447945,0.0001100964,0.0001496857,0.00008421057],"category_scores_gemma":[0.0002013403,0.0001358591,0.0001036864,0.00002007951,0.0001950639,0.00009742996,0.00006457149,0.0001044044,0.00006529544],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001792757,"about_ca_system_score_gemma":0.0002305938,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00008693938,"about_ca_topic_score_gemma":0.00007665849,"domain_scores_codex":[0.9990714,0.00002334552,0.0001872261,0.0003253462,0.0001062063,0.0002865108],"domain_scores_gemma":[0.9988885,0.0001219812,0.0001465556,0.0004631882,0.00007062799,0.0003091822],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.007134652,0.005110798,0.1496293,0.001097482,0.0007688157,0.002796629,0.001889915,0.000002466601,0.006887501,0.00219223,0.0808091,0.7416811],"study_design_scores_gemma":[0.01590699,0.001433643,0.07934411,0.00007240094,0.0009927317,0.00006201601,0.0001109398,0.0002392779,0.0008826839,0.0008788519,0.8998377,0.0002386954],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.948798,0.0008388961,0.000211968,0.01731509,0.0004345622,0.0009195135,0.0001681944,0.00005569261,0.03125806],"genre_scores_gemma":[0.9897346,0.000161866,0.00111845,0.002346581,0.0002430956,0.0001911964,0.00006959761,0.00003051975,0.006104101],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.8190286,"threshold_uncertainty_score":0.5540173,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0307705264303714,"score_gpt":0.3246722442241393,"score_spread":0.2939017177937679,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}